Health Watch: Asthma Drug That May Prevent The Onset Of Preterm Birth On Trial

A clinical trial with the aim of delaying the onset of premature labor is set to start this month. Funded by preterm birth charity Borne and children’s charity Action Medical Research, this exciting new trial will be using a first-line medicine prescribed by the NHS for the treatment of asthma, in combination with progesterone, to delay the onset of premature labor.

Around the world, 15 million babies are born too soon every year and more than 1 million die as a direct consequence. Medical research into preterm birth is significantly under-funded when compared with cancer and heart disease, and so much about what causes preterm birth remains unknown.

Mark Johnson, Borne’s Founder and Professor at the Imperial College where the clinical trial will be conducted, is the lead of a study of potential new treatment in 50 years that could help delay the onset of preterm labour. The study that will assess the efficacy of combining aminophylline, a smooth muscle relaxant and anti-inflammatory, with the hormone progesterone as a treatment administered to women who are at high risk of early labour. By repurposing an existing, readily available drug, the study could change the future for millions of unborn children.

We certainly wish the absolute best for this trial as it has global generational ramifications ~ JD

SHARE ON FACEBOOK SHARE ON TWITTER

Tags: #healthwatch, #HypeCares, Action Medical Research, Borne, Children's Issues, medical research, premature birth, Premature Labor, The Hype Magazine

About the Author

Dr. Jerry Doby Editor-in-Chief of The Hype Magazine, Media and SEO Consultant, Journalist, Ph.D. and retired combat vet. 2023 recipient of The President's Lifetime Achievement Award. Partner at THM Media Group. Member of the U.S. Department of Arts and Culture, the United States Press Agency and ForbesBLK.